Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.51 |
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843644 | 0.92 | TSHR (0.53) | DPP4TSHRALDH1A1LMNAMAPT | |
| SCHEMBL6846144 | 0.92 | DPP4 (0.49) | DPP4TSHRALDH1A1LMNAMAPT | |
| SCHEMBL6838716 | 0.90 | DPP4 (0.53) | DPP4TSHRALDH1A1LMNAMAPT | |
| SCHEMBL6838812 | 0.90 | DPP4 (0.53) | DPP4TSHRALDH1A1LMNAMAPT | |
| SCHEMBL6846148 | 0.90 | DPP4 (0.48) | DPP4TSHRALDH1A1LMNAMAPT | |
| SCHEMBL6843487 | 0.89 | DPP4 (0.54) | DPP4TSHRALDH1A1LMNAMAPT | |
| SCHEMBL6838791 | 0.89 | DPP4 (0.47) | DPP4TSHRALDH1A1LMNAMAPT | |
| SCHEMBL7008737 | 0.87 | MAPT (0.49) | DPP4TSHRALDH1A1LMNAMAPT | |
| SCHEMBL6843776 | 0.87 | DPP4 (0.50) | DPP4TSHRALDH1A1LMNAMAPT | |
| SCHEMBL3970061 | 0.87 | DPP4 (0.67) | DPP4TSHRALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | DPP4 1/4885TSHR 2158/4885ALDH1A1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.